Cardiovascular Risk Factors, Ageing and Dementia (CAIDE) risk score serves as a credible predictor of an individual’s risk of dementia. However, studies on the link of the CAIDE score to Alzheimer’s disease (AD) pathology are scarce.
Objective:
To explore the links of CAIDE score to cerebrospinal fluid (CSF) biomarkers of AD as well as to cognitive performance.
Methods:
In the Chinese Alzheimer’s Biomarker and LifestylE (CABLE) study, we recruited 600 cognitively normal participants. Correlations between the CAIDE score and CSF biomarkers of AD as well as cognitive performance were probed through multiple linear regression models. Whether the correlation between CAIDE score and cognitive performance was mediated by AD pathology was researched by means of mediation analyses.
Results:
Linear regression analyses illustrated that CAIDE score was positively associated with tau-related biomarkers, including pTau (p < 0.001), tTau (p < 0.001), as well as tTau/Aβ42 (p = 0.008), while it was in negative association with cognitive scores, consisting of MMSE score (p < 0.001) as well as MoCA score (p < 0.001). The correlation from CAIDE score to cognitive scores was in part mediated by tau pathology, with a mediation rate varying from 3.2% to 13.2%.
Conclusions:
A higher CAIDE score, as demonstrated in our study, was linked to more severe tau pathology and poorer cognitive performance, and tau pathology mediated the link of CAIDE score to cognitive performance. Increased dementia risk will lead to cognitive decline through aggravating neurodegeneration.
JankaZ, JuhászA, RimanóczyAA, BodaK, Márki-ZayJ, KálmánJ (2002) Codon 311 (Cys–>Ser) polymorphism of paraoxonase-2 gene is associated with apolipoprotein E4 allele in both Alzheimer’s and vascular dementias. Mol Psychiatry7, 110–112.
8.
LicherS, LeeningMJG, YilmazP, WoltersFJ, HeeringaJ, BindelsPJE, VernooijMW, StephanBCM, SteyerbergEW, IkramMK, IkramMA (2019) Development and validation of a dementia risk prediction model in the general population: An analysis of three longitudinal studies. Am J Psychiatry176, 543–551.
9.
AnsteyKJ, CherbuinN, HerathPM, QiuC, KullerLH, LopezOL, WilsonRS, FratiglioniL (2014) A self-report risk index to predict occurrence of dementia in three independent cohorts of older adults: The ANU-ADRI. PLoS One9, e86141.
10.
SchiepersOJG, KöhlerS, DeckersK, IrvingK, O’DonnellCA, van den AkkerM, VerheyFRJ, VosSJB, de VugtME, van BoxtelMPJ (2018) Lifestyle for Brain Health (LIBRA): A new model for dementia prevention. Int J Geriatr Psychiatry33, 167–175.
11.
KivipeltoM, NganduT, LaatikainenT, WinbladB, SoininenH, TuomilehtoJ (2006) Risk score for the prediction of dementia risk in 20 years among middle aged people: A longitudinal, population-based study. Lancet Neurol5, 735–741.
12.
ExaltoLG, QuesenberryCP, BarnesD, KivipeltoM, BiesselsGJ, WhitmerRA (2014) Midlife risk score for the prediction of dementia four decades later. Alzheimers Dement10, 562–570.
13.
VirtaJJ, HeikkiläK, PerolaM, KoskenvuoM, RäihäI, RinneJO, KaprioJ (2013) Midlife cardiovascular risk factors and late cognitive impairment. Eur J Epidemiol28, 405–416.
14.
HouXH, FengL, ZhangC, CaoXP, TanL, YuJT (2019) Models for predicting risk of dementia: A systematic review. J Neurol Neurosurg Psychiatry90, 373–379.
15.
WittmannFG, ZülkeA, PabstA, LuppaM, ThyrianJR, KästnerA, HoffmannW, KaduszkiewiczH, DöhringJ, EscalesC, GensichenJ, ZöllingerI, KosilekRP, WieseB, OeyA, KönigHH, BrettschneiderC, FreseT, Riedel-HellerSG (2023) COVID-19 government measures and their impact on mental health: A cross-sectional study of older primary care patients in Germany. Front Public Health11, 1141433.
16.
HuaR, XiongJ, LiG, ZhuY, GeZ, MaY, FuM, LiC, WangB, DongL, ZhaoX, MaZ, ChenJ, GaoX, HeC, WangZ, WeiW, WangF, GaoX, ChenY, ZengQ, XieW (2022) Development and validation of a deep learning algorithm based on fundus photographs for estimating the CAIDE dementia risk score. Age Ageing51, afac282.
17.
ShahA, Ysea-HillO, Torres-MoralesA, GomezCJ, CastellanosA, RuizJG (2022) Identifying dementia risk in older veterans using a mailing survey. J Prev Alzheimers Dis9, 371–375.
18.
LockhartSN, SchaichCL, CraftS, SachsBC, RappSR, JungY, WhitlowCT, Solingapuram SaiKK, ClevelandM, WilliamsBJ, BurkeGL, BertoniA, HaydenKM, HughesTM (2022) Associations among vascular risk factors, neuroimaging biomarkers, and cognition: Preliminary analyses from the Multi-Ethnic Study of Atherosclerosis (MESA). Alzheimers Dement18, 551–560.
19.
Iso-MarkkuP, KaprioJ, LindgrenN, RinneJO, VuoksimaaE (2021) Middle-age dementia risk scores and old-age cognition: A quasi-experimental population-based twin study with over 20-year follow-up. J Neurol Neurosurg Psychiatry92, 323–330.
20.
RoweCC, EllisKA, RimajovaM, BourgeatP, PikeKE, JonesG, FrippJ, Tochon-DanguyH, MorandeauL, O’KeefeG, PriceR, RanigaP, RobinsP, AcostaO, LenzoN, SzoekeC, SalvadoO, HeadR, MartinsR, MastersCL, AmesD, VillemagneVL (2010) Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging31, 1275–1283.
21.
IngalaS, De BoerC, MasselinkLA, VergariI, LorenziniL, BlennowK, ChételatG, Di PerriC, EwersM, van der FlierWM, FoxNC, GispertJD, HallerS, MolinuevoJL, Muniz-TerreraG, MutsaertsHJ, RitchieCW, RitchieK, SchmidtM, SchwarzAJ, VermuntL, WaldmanAD, WardlawJ, WinkAM, WolzR, WottschelV, ScheltensP, VisserPJ, BarkhofF (2021) Application of the ATN classification scheme in a population without dementia: Findings from the EPAD cohort. Alzheimers Dement17, 1189–1204.
22.
HouXH, BiYL, TanMS, XuW, LiJQ, ShenXN, DouKX, TanCC, TanL, YuJT (2019) Genome-wide association study identifies Alzheimer’s risk variant in MS4A6A influencing cerebrospinal fluid sTREM2 levels. Neurobiol Aging84, 241.e213–241.e220.
23.
ZülkeAE, LuppaM, RöhrS, WeißenbornM, BauerA, SamosFZ, KühneF, ZöllingerI, DöhringJ, BrettschneiderC, OeyA, CzockD, FreseT, GensichenJ, HaefeliWE, HoffmannW, KaduszkiewiczH, KönigHH, ThyrianJR, WieseB, Riedel-HellerSG (2021) Association of mental demands in the workplace with cognitive function in older adults at increased risk for dementia. BMC Geriatr21, 688.
SperlingRA, AisenPS, BeckettLA, BennettDA, CraftS, FaganAM, IwatsuboT, JackCR,Jr.,
, KayeJ, MontineTJ, ParkDC, ReimanEM, RoweCC, SiemersE, SternY, YaffeK, CarrilloMC, ThiesB, Morrison-BogoradM, WagsterMV, PhelpsCH (2011) Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 280–292.
27.
JackCR,Jr.,
, KnopmanDS, WeigandSD, WisteHJ, VemuriP, LoweV, KantarciK, GunterJL, SenjemML, IvnikRJ, RobertsRO, RoccaWA, BoeveBF, PetersenRC (2012) An operational approach to National Institute on Aging-Alzheimer’s Association criteria for preclinical Alzheimer disease. Ann Neurol71, 765–775.
28.
AlbertMS, DeKoskyST, DicksonD, DuboisB, FeldmanHH, FoxNC, GamstA, HoltzmanDM, JagustWJ, PetersenRC, SnyderPJ, CarrilloMC, ThiesB, PhelpsCH (2011) The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 270–279.
29.
McKhannGM, KnopmanDS, ChertkowH, HymanBT, JackCR,Jr.,
, KawasCH, KlunkWE, KoroshetzWJ, ManlyJJ, MayeuxR, MohsRC, MorrisJC, RossorMN, ScheltensP, CarrilloMC, ThiesB, WeintraubS, PhelpsCH (2011) The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement7, 263–269.
30.
JiaX, WangZ, HuangF, SuC, DuW, JiangH, WangH, WangJ, WangF, SuW, XiaoH, WangY, ZhangB (2021) A comparison of the Mini-Mental State Examination (MMSE) with the Montreal Cognitive Assessment (MoCA) for mild cognitive impairment screening in Chinese middle-aged and older population: A cross-sectional study. BMC Psychiatry21, 485.
31.
ChenKL, XuY, ChuAQ, DingD, LiangXN, NasreddineZS, DongQ, HongZ, ZhaoQH, GuoQH (2016) Validation of the Chinese Version of Montreal Cognitive Assessment Basic for Screening Mild Cognitive Impairment. J Am Geriatr Soc64,e285–e290.
ChenDG, PoundsJG (1998) A nonlinear isobologram model with Box-Cox transformation to both sides for chemical mixtures. Environ Health Perspect106(Suppl 6), 1367–1371.
34.
PreacherKJ, HayesAF (2004) SPSS and SAS procedures for estimating indirect effects in simple mediation models. Behav Res Methods Instrum Comput36, 717–731.
35.
SobelME (1982) Asymptotic confidence intervals for indirect effects in structural equation models. Sociol Methodol13, 290.
36.
StephenR, NganduT, LiuY, PeltonenM, AntikainenR, KemppainenN, LaatikainenT, LötjönenJ, RinneJ, StrandbergT, TuomilehtoJ, VanninenR, SoininenH, KivipeltoM, SolomonA (2021) Change in CAIDE dementia risk score and neuroimaging biomarkers during a 2-year multidomain lifestyle randomized controlled trial: Results of a post-hoc subgroup analysis. J Gerontol A Biol Sci Med Sci76, 1407–1414.
EnacheD, SolomonA, CavallinL, KåreholtI, KrambergerMG, AarslandD, KivipeltoM, EriksdotterM, WinbladB, JelicV (2016) CAIDE Dementia Risk Score and biomarkers of neurodegeneration in memory clinic patients without dementia. Neurobiol Aging42, 124–131.
40.
FaganAM (2015) What does it mean to be ‘amyloid-positive’? . Brain138, 514–516.
41.
LiuY, TanY, ZhangZ, YiM, ZhuL, PengW (2024) The interaction between ageing and Alzheimer’s disease: Insights from the hallmarks of ageing. Transl Neurodegener13, 7.
42.
IadecolaC, GottesmanRF (2019) Neurovascular and cognitive dysfunction in hypertension. Circ Res124, 1025–1044.
43.
WellerRO, BocheD, NicollJAR (2009) Microvasculature changes and cerebral amyloid angiopathy in Alzheimer’ s disease and their potential impact on therapy. Acta Neuropathol118, 87–102.
44.
ZlokovicBV (2011) Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders. Nat Rev Neurosci12, 723–738.
45.
TesseurI, Van DorpeJ, SpittaelsK, Van den HauteC, MoecharsD, Van LeuvenF (2000) Expression of human apolipoprotein E4 in neurons causes hyperphosphorylation of protein tau in the brains of transgenic mice. Am J Pathol156, 951–964.
46.
NelsonPT, AlafuzoffI, BigioEH, BourasC, BraakH, CairnsNJ, CastellaniRJ, CrainBJ, DaviesP, Del TrediciK, DuyckaertsC, FroschMP, HaroutunianV, HofPR, HuletteCM, HymanBT, IwatsuboT, JellingerKA, JichaGA, KövariE, KukullWA, LeverenzJB, LoveS, MackenzieIR, MannDM, MasliahE, McKeeAC, MontineTJ, MorrisJC, SchneiderJA, SonnenJA, ThalDR, TrojanowskiJQ, TroncosoJC, WisniewskiT, WoltjerRL, BeachTG (2012) Correlation of Alzheimer disease neuropathologic changes with cognitive status: A review of the literature. J Neuropathol Exp Neurol71, 362–381.
47.
CoradduzzaD, SeddaS, CrucianiS, De MiglioMR, VenturaC, NivoliA, MaioliM (2023) Age-related cognitive decline, focus on microbiome: A systematic review and meta-analysis. Int J Mol Sci24, 13680.
48.
NumakawaT, OdakaH (2022) The role of neurotrophin signaling in age-related cognitive decline and cognitive diseases. Int J Mol Sci23, 7726.
49.
LövdénM, FratiglioniL, GlymourMM, LindenbergerU, Tucker-DrobEM (2020) Education and cognitive functioning across the life span. Psychol Sci Public Interest21, 6–41.
50.
SternY (2012) Cognitive reserve in ageing and Alzheimer’s disease. Lancet Neurol11, 1006–1012.
51.
UngvariZ, TothP, TarantiniS, ProdanCI, SorondF, MerkelyB, CsiszarA (2021) Hypertension-induced cognitive impairment: From pathophysiology to public health. Nat Rev Nephrol17, 639–654.
52.
HöttingK, RöderB (2013) Beneficial effects of physical exercise on neuroplasticity and cognition. Neurosci Biobehav Rev37, 2243–2257.
53.
HawkinsMA, GathrightEC, GunstadJ, DolanskyMA, RedleJD, JosephsonR, MooreSM, HughesJW (2014) The MoCA and MMSE as screeners for cognitive impairment in a heart failure population: A study with comprehensive neuropsychological testing. Heart Lung43, 462–468.
